click enter text
report financi result friday market open
revenu ep beat rais guidanc slightli
also announc increas dividend
fairli quiet quarter overal sourc disappoint humira
hematolog product imbruvica venclexta modestli ahead
revenu ep estim rise averag rais
pt vs previous repres price-to-earnings multipl vs
updat pro-forma ep impli multipl stand-
alon estim note howev target compani allergan
yet report may caus estim chang exhibit
show new abbv agn pro-forma estim
bodi report full analysi
rate peer-perform addit detail
us/eu drug compani cover see global pharmaceut
septemb issu monthli controversi report
host firesid chat variou member
manag wednesday wolf research healthcar
confer click regist view agenda
trade fundament data
upsid target
factset/wolf research price
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
friday open
report result slightli beat consensu revenu ep
rais revenu ep guidanc modestli announc dividend increas
saw share price rise day outperform peer group averag move
overal impress report result slightli ahead consensu rais
guidanc modest degre variou metric limit ep quiet quarter overal major
new news compani increas dividend notabl keep yield current share
price level analyst question broad base put particular emphasi hematolog portfolio
continu well imbruvica venclexta regard azn calquenc azn manag
talk recent competitor imbruvica remain dismiss cll data come
head head head head data come continu import monitor
especi context azn manag say acerta transact could end go
one best deal ever balanc abbv agn continu lower valuat stock attract
dividend yield decis acquir provid meaning buffer combin compani ep
period base current model growth may flat window certainli better
declin stand-alon would invari face exposur humira less
fold still remain high us humira account total compani revenu
model us biosimilar eros time-frame remain uncertainti combin abbv agn catalyst-
lite versu mani peer driven mostli late-stag pipelin thin rate peer-
perform inform stock cover see global pharmaceut septemb
issu monthli controversi report
note host firesid chat variou member manag wednesday
wolf research healthcar confer click regist view agenda
quarterli perform term sale ep exhibit
revenu vs consensu
ep vs consensu
humira sale vs consensu remind third full quarter
biosimilar impact ex-u humira
skyrizi sale vs consensu
imbruvica sale vs consensu
hcv sale vs consensu
venclexta sale vs consensu
page
revenu rais oper fx previou oper
humira guid y/i increas us ex-u sale cer
signal y/i decreas oper quarter
ep revis vs prior consensu
pipelin new materi news announc yesterday posit top-line result select-psa
studi rinvoq jak psoriat arthriti first two registration-en studi indic
revenu increas ep increas
revenu estim increas ep estim rise
depend year
ep compound-annual-growth-rate stand-alon ep compound-annual-growth-rate increas slightli vs prior
repres peer averag growth peer average compound-annual-growth-rate
price target increas vs prior repres new
pro-forma ep estim impli price-to-earnings stand-alon ep estim
target price-to-earnings multipl frequent gone higher part asses updat abbv agn
pro-forma estim see exhibit report
guidanc element revenu growth expect humira us
intenational declin skyrizi imbruvica venclexta hcv approach
gm op margin tax rate rate expect ep
sale growth
 outlook dividend beyond today announc increas claim three main capit alloc
object invest busi pay dividend lower debt would increas dividend doubl
digit cash concern
track close defend strateg merit transact remain commit
nd/ebidta end delevra
page
 statu divestitur relat say continu work ftc request
divest two asset new news sever interest parti remain track close
 close ahead track drive telegraph earlier date
 long rang plan assumpt botox say competit come
two form brand toxin possibl biosimilar former expect see
brand equiti botox strong extrem difficult competitor take share
bundl program place fend competit note built fairli conserv
assumpt track current perform also less agn intern forecast
biosimilar believ would extrem difficult anyon come one expect continu
growth aesthet therapeut segment
sale due biosimilar trend remain consist abbv expect price
 us humira price signific chang price dynam rel
 intenational humira give detail perform on-pat vs off-pat market
biosimilar launch guid eros slightli better
perform better type market come market
imbruvica see recent inflect set coincid updat treatment guidelin venclexta
uptak cll remain good combo data mcl
 view azn acalabrutinib/calqu expect azn show posit data question
take compet effect howev thu far calquenc differenti label
mcl around share cll share despit treatment guidelin
cll imbruvica share share patient well maintain expect
real switch mean new entrant compet mostli new patient segment
go venclexta make inroad
 viabl imbruvica/venclexta combin certain segment combin
would benefici term durat type combin tend fix durat
 azn abl show clinic differenti calquenc either side-by-sid analysi
studi report would like efficaci safeti
say expect see differenti either safeti efficaci product like calquenc continu
look like product safeti see bleed afib calquenc efficaci
proven better wolf comment recal azn comment result manag said
acerta acquisit total could end cost azn may end one best
deal ever bold statement calquenc end show real differenti
page
 imbruvica hypertens side effect someth seen differ btki context
risk benefit remain favor
commerci access uc cd play psoriasi share
grow rapidli
 ex-u skyrizi updat point reimburs small countri extrem
well market expect intenational perform us
rapidli approach play market share enbrel earli jan expect commerci access
eu approv within next month ja describ broad develop program
 big quantifi opportun
approv uf
expect durabl cash flow franchis well next decad
call navitoclax sq levo-/carbodopa call transform
 senat financ committe propos view pocket spend cap
made gener comment support lower pocket spend go
punit expens therapi benefici compani lower price innov therapi
across whole portfolio went could slight net loss balanc
volum uplift lower realiz price
page
exhibit abbvi result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit abbvi guidanc vs wr estim old new
page
oldnewoldnewtot revenuesincreas op oper marginapproach sale higher marginjust interest exp approx tax ratejust tax rate full-year guidancewr estim
exhibit captur chang forecast
exhibit chang wr stand-alon model
page
exhibit show incom statement agn incom statement product revenu
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper revenu earli phase total
exhibit wr balanc sheet cash flow statement
page
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ chang short-term issuanc lt lt debt leas treasuri flow financ activ fx cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock held paid-in comprhens sharehold liabil sharehold
